...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical Medicine Research >Recurrent Body Rash Warranted Second Desensitization With Acyclovir in a Myeloma Patient: A Case Report
【24h】

Recurrent Body Rash Warranted Second Desensitization With Acyclovir in a Myeloma Patient: A Case Report

机译：复发性皮疹保证了阿昔洛韦对骨髓瘤患者的第二次脱敏：一例报告

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

A 75-year-old woman developed a moderately severe rash about a week and a half after the start of bortezomib (Btb)-based chemotherapy for IgG lambda multiple myeloma; at the time, she was also receiving acyclovir as antiviral prophylaxis in addition to herpes zoster (HZ) vaccination. HZ reactivation rate is high in Btb recipients; therefore, the timing of antiviral prevention is critical in relation to Btb. Attempts were made to identify the offending agent based on the timing of drugs administered and the appearance of skin lesions in relation to other drugs. Both Btb and acyclovir were potential culprits. However, the timing of rash presented on days 9 - 10 revealed the offending agent when the corticosteroid was weaned off while acyclovir continued. A decision was made to administer acyclovir rapid desensitization program (RDP) for our patient.J Clin Med Res. 2017;9(8):725-728doi: https://doi.org/10.14740/jocmr2772w
机译：一名75岁妇女在开始使用基于硼替佐米（Btb）的IgG lambda多发性骨髓瘤化疗后约半周出现中度严重皮疹。当时，她除了接受带状疱疹（HZ）疫苗接种外，还接受了阿昔洛韦的抗病毒预防。 Btb受体的HZ激活率很高;因此，相对于Btb，抗病毒预防的时机至关重要。尝试根据给药时间和与其他药物相关的皮肤损伤的出现来识别引起疾病的药物。 Btb和阿昔洛韦都是潜在的罪魁祸首。然而，在第9-10天出现皮疹的时机揭示了当停用阿昔洛韦而皮质类固醇断奶时的病原。决定对我们的患者实施阿昔洛韦快速脱敏计划（RDP）。JClin Med Res。 2017; 9（8）：725-728doi：https://doi.org/10.14740/jocmr2772w

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号